Kidney dosimetry in [ 177 Lu]Lu-DOTA-TATE therapy based on multiple small VOIs

被引:0
|
作者
Kapidzic, Selma Curkic [1 ,2 ,3 ]
Gustafsson, Johan [1 ]
Larsson, Erik [2 ]
Jessen, Lovisa [1 ]
Gleisner, Katarina Sjogreen
机构
[1] Lund Univ, Med Radiat Phys, Lund, Sweden
[2] Skane Univ Hosp, Dept Hematol Oncol & Radiat Phys, Radiat Phys, Malmo, Sweden
[3] Skanes Univ Sjukhus, Barngatan 4, S-22185 Lund, Sweden
关键词
177; Lu-PRRT; Quantitative SPECT; Dosimetry; Kidneys; RECEPTOR RADIONUCLIDE THERAPY; PATIENT-SPECIFIC DOSIMETRY; IMAGE-BASED DOSIMETRY; NEUROENDOCRINE TUMORS; SPECT; ACCELERATION;
D O I
10.1016/j.ejmp.2024.103335
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: The aim was to investigate the use of multiple small VOIs for kidney dosimetry in [ 177 Lu]Lu-DOTA-TATE therapy. Method: The study was based on patient and simulated SPECT images in anthropomorphic geometries. Images were reconstructed using two reconstruction programs (local LundaDose and commercial Hermia) using OS -EM with and without resolution recovery (RR). Five small VOIs were placed to determine the average activity concentration (AC) in each kidney. The study consisted of three steps: (i) determination of the number of iterations for AC convergence based on simulated images; (ii) determination of recovery -coefficients (RCs) for 2 mL VOIs using a separate set of simulated images; (iii) assessment of operator variability in AC estimates for simulated and patient images. Five operators placed the VOIs, using for guidance: a) SPECT/CT with RR, b) SPECT/CT without RR, and c) CT only. For simulated images, time -integrated ACs (TIACs) were evaluated. For patient images, estimated ACs were compared with results of a previous method based on whole -kidney VOIs. Results: Eight iterations and ten subsets were sufficient for both programs and reconstruction settings. Mean RCs (mean +/- SD) with RR were 1.03 +/- 0.02 (LundaDose) and 1.10 +/- 0.03 (Hermia), and without RR 0.91 +/- 0.03 (LundaDose) and 0.94 +/- 0.03 (Hermia). Most stable and accurate estimates of the AC were obtained using five 2mL VOIs guided by SPECT/CT with RR, applying them to images without RR, and including an explicit RC for recovery correction. Conclusion: The small VOI method based on five 2-mL VOIs was found efficient and sufficiently accurate for kidney dosimetry in [ 177 Lu]Lu-DOTA-TATE therapy.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Renal Dosimetry in [177Lu]Lu-DOTA-TATE Therapy Based on Multiple Small VOIs as an Alternative to Whole-Kidney Segmentation
    Curkic, S.
    Gustafsson, J.
    Jessen, L.
    Ljungberg, M.
    Sundlov, A.
    Gleisner, K. Sjogreen
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S639 - S639
  • [2] Peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE
    Prado-Wohlwend, S.
    Bernal-Vergara, J. C.
    Utrera-Costero, A.
    Canon-Sanchez, J. R.
    Agudelo-Cifuentes, M.
    Bello-Arques, P.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2022, 41 (01): : 55 - 65
  • [3] Microfluidic synthesis of [177Lu]Lu-DOTA-TATE
    Liu, Zheng
    Schaap, Kevin
    Rohde, Martin
    Oehlke, Elisabeth
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2017, 60 : S462 - S462
  • [4] Current Practice in Reporting Internal Dosimetry for [177Lu]Lu-DOTA-TATE Therapy: Literature Review
    Ivashchenko, O.
    O'Doherty, J.
    Perez, T.
    Tran-Gia, J.
    Hippelainen, E.
    Sandstrom, M.
    Stokke, C.
    Glatting, G.
    Cremonesi, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S368 - S368
  • [5] Re-treatment with [177Lu]Lu-DOTA-TATE or [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE of patients with progressive neuroendocrine neoplasm
    Durma, Adam Daniel
    Saracyn, Marek
    Kolodziej, Maciej
    Jozwik-Plebanek, Katarzyna
    Mroz, Adrianna
    Kapusta, Waldemar
    Dmochowska, Beata
    Kaminski, Grzegorz
    NUCLEAR MEDICINE REVIEW, 2023, 26 : 143 - 152
  • [6] Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour
    Sejin Ha
    Yong-il Kim
    Jungsu S. Oh
    Changhoon Yoo
    Baek-Yeol Ryoo
    Jin-Sook Ryu
    EJNMMI Physics, 11
  • [7] Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour
    Ha, Sejin
    Kim, Yong-il
    Oh, Jungsu S.
    Yoo, Changhoon
    Ryoo, Baek-Yeol
    Ryu, Jin-Sook
    EJNMMI PHYSICS, 2024, 11 (01)
  • [8] Radiation exposure and protection advice after [177Lu]Lu-DOTA-TATE therapy in China
    Liu, Fei
    Li, Panli
    Xu, Junyan
    Zhang, Jianping
    Xu, Xiaoping
    Chen, Zhihao
    Qiao, Ying
    Liang, Yun
    Chen, Jie
    Song, Shaoli
    EJNMMI RESEARCH, 2024, 14 (01):
  • [9] Preventive measures and management of radiopharmaceutical extravasation with[177Lu]Lu-DOTA-TATE
    Eftychiou, N.
    Fernandez, R.
    Allen, S.
    Lewington, V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S82 - S83
  • [10] Personalized, dosimetry-based PRRT therapy in patients with neuroendocrine tumors using [177Lu]Lu-DOTA-TATE or [177Lu]Lu/[90Y]Y-DOTA-TATE mixture - the initial results of DUONEN multicenter study
    Opalinska, M.
    Kaminski, G.
    Dedecjus, M.
    Kowalska, A.
    Kolodziej, M.
    Saracyn, M.
    Gasior-Perczak, D.
    Lenda-Tracz, W.
    Sowa-Staszczak, A.
    Borkowska, A.
    Budzynska, A.
    Kubik, A.
    Chalewska, W.
    Kacperski, K.
    Szubstarska, P.
    Garnuszek, P.
    Mikolajczak, R.
    Hubalewska-Dydejczyk, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S314 - S314